UPDATE 1-Axsome's Alzheimer's-related drug shows mixed results in late-stage studies
Rewrites paragraph 1, adds detail on trials in paragraphs 2-5
Dec 30 (Reuters) - Axsome Therapeutics AXSM.O said on Monday its experimental drug to treat agitation related to Alzheimer's disease succeeded in one of the two late-stage studies and failed to meet the main goal of the second trial.
Shares of the drug developer, which was testing the treatment, AXS-05, dropped 12% in premarket trading.
The agitation is a symptom that causes emotional distress as well as verbal and physical aggressiveness.
The treatment significantly delayed the time to relapse in agitation as measured on a disease severity scale in one study, but did not demonstrate statistical significance in delaying agitation in another late-stage trial.
AXS-05 was safe and well tolerated in both the studies, the company said.
(Reporting by Sneha S K; Editing by Shilpi Majumdar)
((Sneha.SK@thomsonreuters.com;))
Related Articles
China July Money Supply Commentary: M2 Growth Rises More Than Expected
The relatively large increase in M2 mainly stems from two factors: first, the impact of a low base formed by the relatively low growth rate of M2 in the same period last year; second, the resolution of debts has promoted the improvement of corporate capital flows.
Applied Materials Q3 Earnings: AI Demand Soars, but Cautious Guidance Triggers After-Hours Selloff
TradingKey - Applied Materials, Inc. (NASDAQ: AMAT) announced its Q3 FY2025 earnings on August 14, 2025, after market close, reporting strong revenue fueled by AI-related semiconductor demand, which beat expectations. However, cautious Q4 guidance, including EPS below analyst estimates.jpg)
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing.
U.S. Stocks Surge Wednesday on CPI Data and Strong Bank Earnings
TradingKey - The U.S. stock market rebounded from early January's gloom as core consumer price inflation came in better than expected and some of the largest banks kicked off earnings season on a positive note.
Central Economic Work Conference: China Stocks Fall on Lack of Positive Policy Surprise
TradingKey - For investors in China’s equity markets, the various annual meetings of China’s policymakers are important events. That’s because the macroeconomic considerations – and moves – are much more important in China’s economy, where the government has a big role to play in the execution of bo
